Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that CEO Arthur Sands will present at two virtual conferences in March 2021. The first is the Guggenheim Targeted Protein Degradation Day on March 16, where he will participate in a panel discussion from 10:30 - 11:30 AM EDT. The second is the Oppenheimer 31st Annual Healthcare Conference on March 17 at 3:10 - 3:40 PM EDT, featuring a corporate presentation. Both events will be webcast live, with recordings available post-event on the Nurix website.
- None.
- None.
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate and present at the following conferences in March:
- Guggenheim Targeted Protein Degradation Day Virtual Conference
Tuesday, March 16, 2021 10:30 - 11:30 AM EDT
Panel discussion: Targeted Protein Degradation – Different Approaches, Same Goal? - Oppenheimer 31st Annual Healthcare Conference (Virtual)
Wednesday, March 17th at 3:10 - 3:40 PM EDT
Nurix Corporate Presentation
The discussion and presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. An archived copy of the webcast will be available on the Nurix website for approximately 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.
Contacts:
| Investors: | Media: |
| Jason Kantor, Ph.D. | Elizabeth Wolffe, Ph.D. |
| Nurix Therapeutics, Inc. | Wheelhouse Life Science Advisors |
| jkantor@nurixtx.com | lwolffe@wheelhouselsa.com |
FAQ
What is the date of the Guggenheim Targeted Protein Degradation Day for Nurix Therapeutics?
When will Arthur Sands present at the Oppenheimer Healthcare Conference?
How can I access the webcasts of Nurix's presentations?
What type of company is Nurix Therapeutics?
What technology does Nurix use for drug discovery?
